- Home
- ARQ vs CLLS Comparison
ARQ vs CLLS Comparison
Compare ARQ & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQ
- CLLS
- Stock Information
- Founded
- ARQ 1996
- CLLS 1999
- Country
- ARQ United States
- CLLS France
- Employees
- ARQ N/A
- CLLS N/A
- Industry
- ARQ
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- ARQ
- CLLS Health Care
- Exchange
- ARQ NYSE
- CLLS Nasdaq
- Market Cap
- ARQ 249.0M
- CLLS 240.2M
- IPO Year
- ARQ N/A
- CLLS 2007
- Fundamental
- Price
- ARQ $6.67
- CLLS $1.57
- Analyst Decision
- ARQ Strong Buy
- CLLS Buy
- Analyst Count
- ARQ 1
- CLLS 3
- Target Price
- ARQ $10.00
- CLLS $7.00
- AVG Volume (30 Days)
- ARQ 206.5K
- CLLS 56.7K
- Earning Date
- ARQ 11-07-2024
- CLLS 11-04-2024
- Dividend Yield
- ARQ N/A
- CLLS N/A
- EPS Growth
- ARQ N/A
- CLLS N/A
- EPS
- ARQ N/A
- CLLS N/A
- Revenue
- ARQ $110,023,000.00
- CLLS $36,042,000.00
- Revenue This Year
- ARQ $13.02
- CLLS $271.02
- Revenue Next Year
- ARQ $30.37
- CLLS $33.48
- P/E Ratio
- ARQ N/A
- CLLS N/A
- Revenue Growth
- ARQ 16.44
- CLLS 46.96
- 52 Week Low
- ARQ $2.50
- CLLS $1.53
- 52 Week High
- ARQ $8.26
- CLLS $3.55
- Technical
- Relative Strength Index (RSI)
- ARQ 41.78
- CLLS 27.91
- Support Level
- ARQ $6.28
- CLLS $1.85
- Resistance Level
- ARQ $7.10
- CLLS $2.09
- Average True Range (ATR)
- ARQ 0.33
- CLLS 0.09
- MACD
- ARQ -0.13
- CLLS -0.04
- Stochastic Oscillator
- ARQ 29.32
- CLLS 0.00
About ARQ ARQ INC
Arq Inc is an environmental technology company principally engaged in the sale of consumable air, water, and soil treatment solutions including activated carbon (AC) and chemical technologies. The company manufactures and sells activated carbon and other chemicals used to capture and remove contaminants for the coal-fired power generation, industrial, municipal water and air, water and soil treatment and remediation markets. Some of the products in its portfolio are Powdered Activated Carbon, Granular Activated Carbon, and Colloidal Carbon Product among others.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.